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Celica G. Cosme1, Li Gan2, Lea T. Grinberg1,3, Daniel H. Geschwind4, Giovanni Coppola4, Howard J. Rosen1,
Bruce L. Miller1 and William W. Seeley1,3*
Abstract
Tau aggregation is a hallmark feature in a subset of patients with frontotemporal dementia (FTD). Early and
selective loss of von Economo neurons (VENs) and fork cells within the frontoinsular (FI) and anterior cingulate
cortices (ACC) is observed in patients with sporadic behavioral variant FTD (bvFTD) due to frontotemporal lobar
degeneration (FTLD), including FTLD with tau inclusions (FTLD-tau). Recently, we further showed that these
specialized neurons show preferential aggregation of TDP-43 in FTLD-TDP. Whether VENs and fork cells are prone
to tau accumulation in FTLD-tau remains unclear, and no previous studies of these neurons have focused on
patients with pathogenic variants in the gene encoding microtubule-associated protein tau (FTLD-tau/MAPT). Here,
we examined regional profiles of tau aggregation and neurodegeneration in 40 brain regions in 8 patients with
FTLD-tau/MAPT and 7 with Pick’s disease (PiD), a sporadic form of FTLD-tau that often presents with bvFTD. We
further qualitatively assessed the cellular patterns of frontoinsular tau aggregation in FTLD-tau/MAPT using
antibodies specific for tau hyperphosphorylation, acetylation, or conformational change. ACC and mid-insula were
among the regions most affected by neurodegeneration and tau aggregation in FTLD-tau/MAPT and PiD. In these
two forms of FTLD-tau, severity of regional neurodegeneration and tau protein aggregation were highly correlated
across regions. In FTLD-tau/MAPT, VENs and fork cells showed disproportionate tau protein aggregation in patients
with V337 M, A152T, and IVS10 + 16 variants, but not in patients with the P301L variant. As seen in FTLD-TDP, our
data suggest that VENs and fork cells represent preferentially vulnerable neuron types in most, but not all of the
MAPT variants we studied.
Keywords: Selective vulnerability, Tau, MAPT, von Economo neurons, Anterior cingulate cortex, Insula
Introduction
The frontoinsula (FI) and anterior cingulate cortex (ACC)
are key hubs within a large-scale “salience network” crit-
ical for autonomic and social-emotional functions [1, 2].
These regions are the earliest and most consistently
affected in patients with sporadic behavioral variant fron-
totemporal dementia (bvFTD) [3–5] and represent the
major sites where von Economo neurons (VENs) and fork
cells are located. Early, selective loss of these unique Layer
5 neurons has been demonstrated in patients with spor-
adic bvFTD across the underlying FTLD spectrum, in-
cluding patients with tau-immunoreactive inclusions
(FTLD-tau) [6–11]. In FTLD with transactive response
DNA binding protein 43 kDa (TDP-43) inclusions (FTLD-
TDP), VENs show a striking propensity to form TDP-43
inclusions [12], but whether the same is true for tau aggre-
gation in FTLD-tau remains unstudied. Pick’s disease
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(PiD) is the most common FTLD-tau subtype under-
lying bvFTD, but its severe neuronal loss makes it
difficult to study early neuronal targets of tau aggrega-
tion. Given the growing efforts to model FTLD tauo-
pathy using cell models derived from patients with
FTLD-tau/MAPT [13–15], we reasoned that an assess-
ment of VEN and fork cell vulnerability in this patient
group could provide an important backdrop for the
field. We hypothesized that ACC and FI VENs and
fork cells are prone to tau aggregation in FTLD-tau, as
they are to TDP-43 aggregation in FTLD-TDP. Here,
we combined a semi-quantitative regional analysis
with a qualitative assessment of neuron type-specific
aggregation of tau in ACC and FI. Forty brain regions
were prospectively rated for neurodegeneration and
tau inclusions in 8 patients with FTLD-tau/MAPT and
7 with sporadic bvFTD-PiD. We then focused on tau
aggregation within VENs, fork cells, and neighboring
neurons in patients with FTLD-tau/MAPT represent-
ing four MAPT variants from different exons, introns,
and families (V337 M: exon 12 mutation; P301L: exon
10 mutation; IVS10 + 16: intron 10 mutation; A152T:
risk variant), using monoclonal antibodies labeling tau
acetylation, hyperphosphorylation, and conformational
changes. The findings suggest overlapping regional
and neuron type-specific vulnerability in sporadic and
inherited FTLD-tau.
Material and methods
Patients and autopsy procedures
Post-mortem human brain tissue was obtained from the
UCSF Neurodegenerative Disease Brain Bank. Clinical
diagnoses of bvFTD, non-fluent variant primary progres-
sive aphasia (nfvPPA), and progressive supranuclear
palsy-Richardson syndrome (PSP-RS), were made ac-
cording to prevailing international consensus criteria at
the time of assessment [16, 17]. Neuropathological diag-
noses were made following consensus diagnostic criteria
using previously described histological and immunohis-
tochemical methods [18–20]. Cases were selected based
on clinical and neuropathological diagnoses, and genetic
analysis [7, 21] (Table 1 Additional file 1: Table S1). Ini-
tial brain cutting and processing depended on the site of
brain procurement. For Cases 1–4, 6–8 of FTLD-tau/
MAPT group with Case 3 of PiD group, one cerebral
hemisphere was immersion fixed in 10% buffered forma-
lin indefinitely. The remaining cases were cut freshly
into ~ 1 cm-thick coronal slabs and fixed in 10% neutral
buffered formalin for ~ 72 h. The FTLD-tau/MAPT co-
hort (n = 8) consisted of P301L (exon 10; n = 2, rela-
tives), IVS10 + 16 (intron 10; n = 3, relatives), V337M
(exon 12, n = 1), and A152T (n = 2, unrelated families).
Regional involvement in FTLD-tau/MAPT was com-
pared to sporadic bvFTD due to PiD (n = 7).
Immunohistochemistry
Twenty-five standard diagnostic fixed paraffin-embedded
tissue blocks, encompassing 40 distinct brain regions for
each brain, were cut from one hemisphere into 8 μm-thick
sections, mounted on glass slides, deparaffinized, and
stained. For phospho-tau immunostaining, paraffin sec-
tions underwent heat-induced antigen retrieval using an
autoclave at 121 °C in citrate buffer, pH 6.0 for 5min. Sec-
tions were then incubated with an established antibody
CP13 (mouse monoclonal, targeting pSer202, gift from
Peter Davies [22]) overnight at room temperature. Follow-
ing incubation with CP13, sections were next incubated at
room temperature for 40min with biotinylated secondary
antibody (1200, Vector Laboratories) before incubation
for 30min with avidin-biotin-peroxidase complexes (1100,
VECTASTAIN Elite Kit, PK-6100, Vector Laboratories).
Staining was developed using the chromogen 3,3-diamino-
benzidine tetrahydrochloride (DAB; Fisher) /H2O2 and
sections were counterstained with Hematoxylin before
coverslipping in Permaslip (Alban Scientific).
For free-floating immunohistochemistry, tissue blocks
from ACC and FI were dissected from ~ 1 cm thick
formalin-fixed coronal slabs, immersed in graded su-
crose solutions (10, 20, 30% sucrose in PBS with sodium
azide), and sectioned on a sliding microtome into alter-
nating series of 300- and 50 μm- sections. Every 12th
section was Nissl-stained with cresyl violet (FD Neuro-
Technologies) to determine the anatomical boundaries
of the region of interest. Three sections from each block
were stained for tau hyperphosphorylation (CP13), acetyl-
ation (MAB359; rabbit monoclonal, targeting K274, gift
from Li Gan [23]), or conformational changes (MC1;
mouse monoclonal, gift from Peter Davies [24]). Sections
were thoroughly rinsed in 0.01M PBS (6 × 10min).
MAB359-stained sections were pre-treated with 88% for-
mic acid for 5 min and then underwent antigen retrieval
in 10mM citrate buffer, pH 6.0 for 5 min at 121 °C. MC1-
stained sections underwent antigen retrieval in 10mM
Tris buffer at pH 9.0 for two hours at 80 °C. CP13-stained
sections underwent antigen retrieval in 10mM citrate buf-
fer pH 6.0 for two hours at 80 °C. After washing with PBS
(3 × 10min), CP13- and MC- stained sections were incu-
bated in 3% H2O2 diluted in PBS-Az for 30min to block
endogenous peroxidase activity. Sections were then
washed and incubated in 0.01M PBS containing 0.3% Tri-
ton X-100 and 10% normal horse or goat serum (Vector
Laboratories, Burlingame, CA, USA) for 1 h, followed by
incubation with CP-13 (1:5000), MAB359 (1:10,000), or
MC1 (1:500) in 0.01M PBS containing 0.3% Triton X-100,
10% normal serum for 48 h at 4 °C. Sections were then
incubated with biotinylated secondary antibody (horse
anti-mouse or goat anti-rabbit IgG; Vector Laboratories,
Burlingame, CA; 1:500) in antibody buffer for one hour at
room temperature. Sections were then washed and
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incubated with avidin-biotin-peroxidase complexes (Vec-
tastain Elite Kit, PK-6100, Vector Laboratories, 1:500 each
in PBT) for one hour. After washing, immunostaining was
developed with DAB. Selected sections were counter-
stained with thionin (PS101–02; FD NeuroTechnologies).
A Nikon 80i microscope was used for bright-field micros-
copy. Photomicrographs were taken using a Nikon Digital
Sight DS-Fi1 camera and NIS Elements D 3.2 software.
Neuropathological evaluation
For regional semi-quantitaive analysis, we performed
routine immunohistochemistry and assessments with a
single 8 μm-thick section from each standard diagnostic
fixed paraffin-embedded tissue block. For cellular quali-
tative analysis, we performed free-floating immunohisto-
chemistry and assessments with three 50 μm-thick
sections equally spaced throughout each ACC and FI tis-
sue block. Stained sections from a standard set of brain
regions were prospectively assessed by one of three
trained examiners (WWS, LTG, or SS). Pathological
diagnostic, staging, and semi-quantitative regional
neuropathological data were performed by one of three
expert examiners (WWS, LTG, or SS) and reviewed at a
consensus case conference. The assessments were per-
formed prospectively without knowledge of the study hy-
potheses but were not blinded to clinical or genetic
information. Examiners meet regularly to promote reli-
ability of these prospective diagnostic assessments. Non-
specific features of neurodegeneration were scored based
on the hematoxylin and eosin (H&E) stain and included
microvacuolation, astrogliosis, and neuronal loss, each
graded on a 0 to 3 scale (absent, mild, moderate, severe).
Tau aggregates were visualized based on CP13 staining
and rated using the same 0–3 scale for neurofibrillary
tangles, Pick bodies, (other) neuronal cytoplasmic inclu-
sions, globose tangles, astrocytic plaques, tufted astro-
cytes, thorny astrocytes, tau-positive threads and grains
in the gray and white matter, and (other) glial cytoplas-
mic inclusions. We generated neurodegeneration scores
for each region in each case by adding the score of
“neuronal loss” to the average of the scores for “vacuol-
ation” and “gliosis” based on the H&E stain for each re-
gion in each case. The tau scores were the average
scores across “neurofibrillary tangles,” “Pick bodies,”
“(other) neuronal cytoplasmic inclusions,” “globose tan-
gles,” “astrocytic plaques,” “tufted astrocytes,” “thorn-
shaped astrocytes,” “tau-positive threads,” and grains in
the gray and white matter, and (other) glial cytoplasmic
inclusions. To analyze the overall pattern pathological
changes, we calculated a composite score for each region
by adding the tau and neurodegeneration scores; we
then averaged composite scores across subjects for each
region. The median composite score was used to rank
order brain regions within each patient group. For
patients with FTLD-tau/MAPT, thick sections submitted
for immunohistochemistry were assessed qualitatively to
determine the pattern of VEN vs. neighboring neuron
tau aggregation propensity. PiD cases showed advanced
stages of disease with massive loss of VENs and fork
cells, making them unsuitable for assessment of tau ag-
gregation at the cellular level.
Statistical analysis
Pearson’s correlation tests for linear regression were per-
formed using GraphPad Prism 8 to assess the associa-
tions between neurodegeneration and tau aggregation
scores across each brain region in FTLD-tau/MAPT and
FTLD-PiD. We employed a p < 0.05 (two-tailed) thresh-
old for a statistical significance.
Results
FTLD-tau/MAPT and PiD share prominent involvement of
ACC and mid-insular cortex
To evaluate how our patients with FTLD-tau/MAPT
(n = 8) compared to patients with bvFTD due to spor-
adic PiD (n = 7), we assessed regional neurodegeneration
(ND) and tau aggregation in 40 brain regions per case.
As expected, we found a strong positive correlation be-
tween ND and tau aggregation across brain regions in
FTLD-tau/MAPT (r = 0.74, p < 0.0001) and in PiD
(r = 0.84, p < 0.0001) (Fig. 1a). The pattern of regional in-
volvement also suggested a substantial overlap between
groups, including severe degeneration in the pre- and
sub-genual ACC and mid-insular cortex. Notably, tau
burden in FTLD-tau/MAPT and PiD reached a plateau
in the presence of severe neurodegeneration. As in PiD,
in FTLD-tau/MAPT the ACC subregions and insula
were among the ten most affected regions, based on the
regional composite scores (Fig. 1b). In addition to ACC
and middle insula, amygdala and PAG, also nodes within
the salience network, were among the 10 most affected
regions in FTLD-tau/MAPT. The other 7 most-affected
regions for FTLD-tau/MAPT were included in the top
10 for PiD. Overall, the FTLD-tau/MAPT cases had a
similar ranking of regional burden to the PiD cases.
P301L cases showed the most severe tau burden, with
relatively high composite scores across most regions, in-
cluding those in the salience network, followed by
IVS10 + 16 cases, then V337M. As expected, the A152T
case with underlying PSP, which primarily affects sub-
cortical and brainstem structures, showed the mildest
tau deposition in cortical regions.
VENs and fork cells in most FTLD-tau/MAPT variants show
disproportionate tau aggregation featuring
phosphorylation and acetylation
Having confirmed that the ACC and mid-insula were
both prominently affected in FTLD-tau/MAPT, we next
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focused on whether ACC and FI VENs and fork cells
[25, 26] showed an increased propensity to aggregate tau
compared to neighboring neurons. This hypothesis of
selective neuronal vulnerability was supported by the
pattern of tau hyperphosphorylation in the patients with
the V337M variant (Fig. 2a-d) and A152T variant
(Fig. 2i-o), who showed neurofibrillary tangle-like cyto-
plasmic inclusions, all 3 patients with the IVS10 + 16
variant (Fig. 2e-h), who showed a more diffuse/granular
inclusion type, but not in the two patients with the
P301L variant (Fig. 2p-t). All of these patients presented
with bvFTD. The MAPT A152T rare variant is consid-
ered a risk factor for tauopathies including FTLD-tau
and AD [27], and we included both of the patients with
this variant available within the UCSF Neurodegenera-
tive Disease Brain Bank. Staining for hyperphosphory-
lated tau revealed that tau aggregates typically filled the
VEN and fork cell somata and continued into proximal
apical and basal dendrites in the FTLD-PSP/A152T case
(Fig. 2m-o). Despite the sparse tau aggregation in the
ACC and insula, VENs and fork cells were clearly among
the most, if not the most vulnerable to tau hyperpho-
sphorylation (Fig. 2), representing a higher proportion of
inclusion-bearing neurons than predicted by their low
prevalence within Layer 5 (2–5% in control brains, de-
pending on region and subregion) [28]. The patterns of
tau aggregation differed between the two patients with
the A152T variant, not surprisingly given that one had
PSP and the other CBD. The most affected regions in
the FTLD-PSP/A152T case were the subcortical regions
involved in motor function, including dentate nucleus,
tectum, substantia nigra, global pallidus, as typically seen
in patients with Richardson syndrome due to PSP. Thus,
the FTLD-PSP/A152T case provided valuable informa-
tion about the most vulnerable cortical neuron popula-
tions at an early stage of tau aggregation (Fig. 2i-o). The
patients with FTLD-CBD/A152T presented with non-
fluent variant primary progressive aphasia at an ad-
vanced stage. The cortical regions, including ERC, pos-
terior cingulate cortex, middle frontal gyrus, inferior
temporal gyrus, middle insula, angular gyrus, and anter-
ior midcingulate cortex, were most affected. Most hyper-
phosphorylated tau labeling in the CBD/A152T case was
seen in threads and neuronal cytoplasmic inclusions in
the ACC, and a few labeled neuronal cytoplasmic inclu-
sions in the FI. In contrast, the two patients with the
P301L variant showed a heavy tau burden more promin-
ent in Layer 6 than 5, with conspicuous sparing of VENs
and fork cells (Fig. 2r, t-p) despite a clinical presentation
of bvFTD.
The dense burden of neuropil tau hyperphosphory-
lation seen in some patients and regions precluded
clear inferences about relative cell-type vulnerabil-
ities. Therefore, we further employed an antibody to
tau acetylated at K274, which generally labels acety-
lated tau contained within the proximal neuron but not
Fig. 1 a Correlation of neurodegeneration and tau pathology in the FTLD-tau/MAPT and PiD cases across regions. b Ten most affected regions in
the FTLD-tau/MAPT cases showed similar ranking of regional burden as PiD cases. The insular and cingulate cortex are highlighted between
dashed lines
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more distal processes that compose the neuropil. This
strategy allowed us to assess tau acetylation in VENs and
fork cells while also gaining a clearer picture of cell type
specificity (Fig. 3).
The identified VENs and fork cell inclusions adopted a
neurofibrillary character consistent with the six-isoform
nature of the V337M tauopathy (Figs. 2 and 3). In the
patient with the V337M variant (Fig. 3a-d), tau acetyl-
ation was predominantly in Layer 5 (Fig. 3a-b), and a
qualitative survey revealed most of these were VENs and
fork cells. In IVS10 + 16 cases, the tau aggregates in
VENs and fork cells were less fibrillary, forming more
diffuse, patchy and granular material within the cyto-
plasm (Fig. 3e-h). Grains were copious in the ventral
(agranular, VEN/fork cell-containing) anterior insula but
sparse in dorsal (dysgranular, VEN/fork cell-lacking) an-
terior insula in all 3 patients with the IVS10 + 16 variant,
all of whom shared a common tau deposition pattern,
with abundant acetylated and hyperphosphorylated tau
grains in the superficial layers and relatively few acety-
lated tau-positive neuronal cytoplasmic inclusions in
superficial or deep layers. VENs and fork cells were
clearly represented among the few inclusion-bearing
neurons, despite their low prevalence in the tissue, indi-
cating a predisposition toward inclusion formation in
the IVS10 + 16 variant. Acetylated tau-positive neuronal
cytoplasmic inclusions in the PSP/A152T case (Fig. 3i-l)
showed a pattern similar to but less frequent than of the
stains for tau hyperphosphorylation (Fig. 2i-o). As previ-
ously shown in CBD [23], most acetylated tau labeling in
the CBD/A152T case was seen in astrocytic plaques with
few labeled neuronal cytoplasmic inclusions. In the P301L
cases, acetylated tau findings mirrored those seen with
hyperphosphorylated tau. VEN and fork cell numbers
appeared relatively normal, and those cells identified in
Nissl-counterstained materials rarely showed tau acetyl-
ation (Fig. 3m-p), despite severe degeneration in the ACC
and mid-insula (Fig. 1b).
VENs and fork cells in most FTLD-tau/MAPT variants show
conformational changes of tau
Conformational changes in the tau protein modify its
function [29, 30]. To test whether VENs and fork
cells show tau conformational changes in FTLD-tau/
MAPT, we used a conformation-specific monoclonal
antibody (MC1), which detects a discontinuous, con-
formational epitope of tau protein at amino acid resi-
dues 7–9 and 312–322 in the third microtubule
binding domain. In V337M, MC1-positive inclusions
were very sparse, but VENs and fork cells were prom-
inent among the labeled neurons (Fig. 4a-d). The
IVS10 + 16 and A152T cases demonstrated formation
of pre-tangle-like inclusions in VENs and fork cells,
affecting only a subset of the tau inclusion-bearing
cells expected based on other staining methods (Fig.
4e-l). In the P301L cases, VENs and fork cells were
Fig. 2 VENs (black arrowheads) and fork cells (red arrowheads) showed a high rate of hyperphosphorylated tau inclusion formation compared to
neighboring neurons in Layer 5 in patients with V337 M (a-d), IVS10 + 16 (e-h), A152T (i-o); but not the P301L variant (p-t). Scale bars: a, e, i, p =
100 μm; b, d, f, h, j, l, q-t = 50 μm; c, g, k = 25 μm; m-o = 10 μm
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again conspicuously spared despite widespread MC-1
staining in general (Fig. 4m-p). We found higher rates
of MC1 immunoreactivity in IVS10 + 16 and P301L,
followed by V337M and lastly the A152T cases.
Taken together, our findings suggest that VENs and
fork cells are predisposed to tau aggregation in FTLD-
tau/MAPT with V337M, IVS + 16, and A152T variants
but may be less vulnerable, in patients with the P301L
variant (Table 2).
Discussion
Sporadic and familial bvFTD are associated with neuro-
degeneration that either begins in or quickly spreads to
the ACC and FI [4, 31–33]. Targeting of these regions
has been linked to selective dropout of VENs and fork
cells [6–10, 12], but to date no study has assessed tau in-
clusion formation within these neurons. Here, we used a
qualitative approach to show that bvFTD due to inher-
ited FTLD-tau, like sporadic bvFTD due to PiD, shows
an anatomical pattern that prominently includes the
ACC and FI. We focused our VEN/fork cell assessment
on FTLD-tau/MAPT because the VEN-containing re-
gions in PiD were too degenerate to enable a conclusive
anatomical assessment. Our FTLD-tau/MAPT findings
showed frequent tau inclusions in VENs and fork cells,
out of proportion to the abundance of these neurons in
the tissue, in patients with the V337M, IVS + 16, and
A152T variants (Table 2). Findings from the FTLD-PSP/
A152T case suggested that VENs and fork cells were af-
fected during the early stages of cortical involvement, at
a time when Layer 2–3 neurons are just beginning to
form tau inclusions and neighboring Layer 5 neurons re-
main largely spared. Intriguingly, our two patients with
the P301L variant showed conspicuous sparing of these
neurons. Although these findings should be viewed with
caution in light of the small sample sizes within each
MAPT variant, our observations suggest that VENs and
fork cells are vulnerable to tau aggregation in FTLD-tau/
Fig. 3 VENs (black arrowheads) and fork cells (red arrowheads) showed a high rate of acetylated tau inclusion formation compared to
neighboring Layer 5 neurons in patients with V337 M (a-d), IVS10 + 16 (e-h), PSP/A152T (i-l), but not the P301L variant (m-p). Scale bars: a, b, e, f,
i, j, m, n = 100 μm; c, d, g, h, k, l, o, p = 10 μm
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MAPT. This vulnerability may interact with the specific
MAPT variant in ways that remain to be explored.
There are several potential implications of this study.
First, our findings suggest the possibility that MAPT var-
iants, and their consequent changes in tau protein struc-
ture and function, direct the pattern of cell type
vulnerability to tau aggregation. This observation pre-
sents an opportunity to explore the interaction between
misfolded tau structures (or “strains”) and neuron type
in determining where disease begins and spreads. Sec-
ond, VEN and fork cell degeneration in ACC and FI is
strongly linked to the bvFTD syndrome, but in the
present study bvFTD emerged in patients with and
without targeted VEN/fork cell tau aggregation. This ob-
servation suggests that phenotypic convergence need not
be determined at the neuron type level and may instead
be driven, in some patients, by neuroanatomical conver-
gence at the regional or network levels. Compared to
Table 2 Summary of pathological tau inclusion patterns in selected patients with FTLD-tau/MAPT
Pathological changes in FTLD-tau/MAPT IVS10 + 16 C- > T V337 M A152T P301L
Cortical Layer NCI distribution 2, 5–6 2, 5–6 5 (PSP) 2, 5–6
Preferential VEN and fork cell tau aggregation Yes Yes Yes No
Hyperphosphorylation at serine 202 (CP13) Yes Yes Yes Yes
Acetylation at k274 (MAB359) Moderate Mild Mild Mild
Tau conformational change in NCIs (MC1) Mild-moderate Mild Absent-Mild Moderate-Severe
Fig. 4 VENs (black arrowheads) and fork cells (red arrowheads) showed a high rate of conformational changes of tau compared to neighboring
Layer 5 neurons in patients with V337 M (a-d), IVS10 + 16 (e-h), and A152T (i-l), but not the P301L variant (m-p). Scale bars: a, b, e, f, i, j, m, n, o,
p = 100 μm; c, d, g, h, k, l = 10 μm
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other MAPT variants, patients with P301L variant showed
relatively high composite scores in the regions linked to the
salience network, including sACC, middle insula, aMCC,
and amygdala. Thus, in some cases, such as P301L, neuro-
anatomical convergence producing the bvFTD syndrome
may occur at the regional or network level. In other words,
dysfunction within ACC, FI, or their salience network part-
ners may prove sufficient to drive social-emotional dysfunc-
tion in bvFTD even when VENs and fork cells remain
intact, as observed in our MAPT P301L variant carriers.
Third, our findings suggest that cell-based assays designed
to model selective vulnerability in vitro may require tailor-
ing to the individual disease-causing or risk variant and its
established selective vulnerability pattern. Fourth, our find-
ings lend additional support for ongoing efforts to differen-
tiate induced pluripotent stem cells and fibroblasts into a
VEN and fork cell lineage, parallel to protocols that derive
motor neuron-like cells for the study of amyotrophic lateral
sclerosis or dopaminergic neurons for the study of Lewy
body disease.
Limitations and future directions
This study was limited by materials available at the UCSF
Neurodegenerative Disease Brain Bank, which resulted in
small samples within each MAPT variant, too small to af-
ford statistical comparisons. Based on these constraints and
the visually striking effects observed in the tissues, we opted
for a qualitative survey of VEN and fork cell tau aggrega-
tion. The stage is set for future larger studies with more
MAPT variants and a quantitative approach to neuron-type
vulnerability assessment. The three IVS10 + 16 cases had
relatively severe neuronal loss, possibly undermining our
ability to detect VENs and fork cells containing tau inclu-
sions. The MC1 antibody used to assess conformational
changes in tau was developed for Alzheimer’s disease and
comparable reagents for these diverse inherited tauopathies
are lacking [34]. Despite these limitations, our findings pro-
vide a foundation for future exploration of selective vulner-
ability in FTLD-tau/MAPT and other FTLD tauopathies.
Conclusions
The available data suggest that some MAPT variants may
converge on these large, specialized neurons through
commonalities among their misfolded tau “strains”, by dis-
rupting some common cellular process critical for VEN/
fork cell survival, or through independent, variant-specific
mechanisms that await exploration.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-019-0809-0.
Additional file 1: Table S1. Alzheimer’s disease-related changes in pa-
tients with FTLD-tau/MAPT and Pick’s disease.
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